Basal cell carcinoma (BCC) is the most common human cancer worldwide, and is a subtype
of nonmelanoma skin cancer, characterized by a constantly increasing incidence due to an …

Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological
adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved …

Hedgehog (Hh) signaling is a highly conserved pathway that plays a vital role during
embryonic development. Recently, uncontrolled activation of this pathway has been …

Glioma represents a fast proliferating and highly invasive brain tumor which is resistant to
current therapies and invariably recurs. Despite some advancements in anti-glioma …

An essential role for Hedgehog (Hh) signaling in human cancer has been established
beyond doubt. At present, targeting Hh signaling has mainly been investigated with SMO …

Basal cell carcinoma (BCC) of the skin is driven by aberrant hedgehog signaling. Thus
blocking this signaling pathway by small molecules such as vismodegib inhibits tumor …

Imiquimod is a synthetic imidazoquinolone amine, which has potent immune response
modifier activity, when topically used. This characteristic property of imiquimod has led to its …

Hedgehog (Hh) signaling has emerged in recent years as an attractive target for anticancer
therapy because its aberrant activation is implicated in several cancers. Major progress has …

Uncontrolled activation of the Hedgehog/Glioma-associated oncogene (HH/GLI) pathway is
a potent oncogenic driver signal promoting numerous cancer hallmarks such as …

Basal cell carcinoma is the most commonly occurring cancer in the world and overall
incidence is still on the rise. While typically a slow-growing tumor for which metastases is …